Genomic Monitoring of H1N1, H3N2, and Influenza B Victoria Lineage Viruses in Qingyang (2020–2023): Analysis of Phylogenetic and Molecular Features of HA and NA Genes - Scorecard - MDSpire
Advertisement
Genomic Monitoring of H1N1, H3N2, and Influenza B Victoria Lineage Viruses in Qingyang (2020–2023): Analysis of Phylogenetic and Molecular Features of HA and NA Genes
Clinical Scorecard: Genomic Monitoring of H1N1, H3N2, and Influenza B Victoria Lineage Viruses in Qingyang (2020–2023): Analysis of Phylogenetic and Molecular Features of HA and NA Genes
At a Glance
Category
Detail
Condition
Key Mechanisms
Target Population
Residents of Qingyang City, China, including vulnerable groups such as young children, elderly, and immunocompromised individuals.
Care Setting
Key Highlights
Continuous surveillance from 2020 to 2023 revealed prevalence of H1N1, H3N2, and B/Victoria strains.
Significant antigenic variability observed in HA and NA genes.
Molecular evolution insights can inform vaccine and antiviral drug development.
Findings may influence public health policy and vaccination strategies.
Guideline-Based Recommendations
Diagnosis
Management
Administer antiviral drugs targeting NA, such as oseltamivir (75 mg twice daily) and zanamivir (10 mg via inhalation twice daily) for 5 days.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Timely antiviral treatment is crucial for effective management of influenza infections, especially in at-risk populations.
Clinical Best Practices
Implement annual influenza vaccination based on WHO recommendations.
Monitor local epidemiological data to inform vaccination strategies.
